Medical Instruments & Supplies

(DXCM) DexCom Stays at Neutral

On May 22, 2013, we reiterated DexCom, Inc. (DXCM) at Neutral based on its first quarter 2013 earnings results.

On May 1, DexCom announced results for the reported quarter. The company incurred adjusted loss per share of 16...

22Aug2013 | | Comments Off on (DXCM) DexCom Stays at Neutral | Continued

(THOR) Thoratec Controller Earns Food and Drug Administration Approval

Thoratec Corp. (THOR), a leader in mechanical circulation support devices, recently revealed that it has received approval from the Food and Drug Administration (FDA) to sell the HeartMate II Pocket Controller meant for use with the...

12Aug2013 | | Comments Off on (THOR) Thoratec Controller Earns Food and Drug Administration Approval | Continued

(PKI) PerkinElmer Downgraded to Underperform

On May 16, 2013, we downgraded our recommendation on PerkinElmer Inc. (PKI) to Underperform based on its first quarter earnings results and reduced guidance.

On Apr 25, PerkinElmer announced its results for the reported quarter....

12Aug2013 | | Comments Off on (PKI) PerkinElmer Downgraded to Underperform | Continued

(BSX) Boston Scientific Entangled in Patent Issues

Medical technology major Boston Scientific Corporation (BSX) was hit by another patent tiff when Germany-based OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH enforced the seizure of more than 190 stent systems...

26Jul2013 | | Comments Off on (BSX) Boston Scientific Entangled in Patent Issues | Continued

(ABMD) Abiomed Releases Encouraging Preliminary Fourth Quarter Data

Leading cardiac assist devices maker, Abiomed Inc. (ABMD), provided encouraging preliminary data for its fourth-quarter 2013 results. The company will report full results on May 2, 2013.

Revenues climbed 17% year over year...

3May2013 | | Comments Off on (ABMD) Abiomed Releases Encouraging Preliminary Fourth Quarter Data | Continued

(COV) Covidien plc Rolls Out More Concerta Drugs

Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), launched more dosages of the Concerta (methylphenidate HCl) Extended-Release (ER) Tablets USP (CII). The company introduced the new 36 mg and 54 mg dosage strengths.

In...

11Apr2013 | | Comments Off on (COV) Covidien plc Rolls Out More Concerta Drugs | Continued

(VVUS) Vivus’ Qsiva Sees Negative Decision From European Medicines Agency

Vivus, Inc. (VVUS) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) re-examined and confirmed its decision about not recommending the approval of weight-loss...

25Feb2013 | | Comments Off on (VVUS) Vivus’ Qsiva Sees Negative Decision From European Medicines Agency | Continued

(BDX) Becton, Dickinson and Company Beats Again – Guides Higher

Medical technology major Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2013 earnings per share from continuing operations of $1.35, reflecting a beat of 9.8% over the Zacks Consensus Estimate.

The company...

7Feb2013 | | Comments Off on (BDX) Becton, Dickinson and Company Beats Again – Guides Higher | Continued

(HAE) Haemonetics – Bull of the Day

2013 is considered a landmark year for Haemonetics (HAE) based on several key growth factors, including entry in the $1.2 billion whole blood collection market with the acquisition of the transfusion medicine business of Pall Corp. We are also...

14Jan2013 | | Comments Off on (HAE) Haemonetics – Bull of the Day | Continued

(MR) Mindray Medical International Limited Downgraded to Neutral

We downgrade our recommendation on Mindray Medical International Limited (MR) to Neutral. Its third-quarter 2012 adjusted (excluding one-time expenses other than stock-based compensation expense) earnings per share of 39 cents missed...

6Jan2013 | | Comments Off on (MR) Mindray Medical International Limited Downgraded to Neutral | Continued

(COV) Covidien Drug Wins U.S. Food and Drug Administration Approval

Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), has won the U.S. Food and Drug Administration (FDA) approval to manufacture and sell a generic version of CONCERTA (methylphenidate HCl) Extended-Release (ER) Tablets...

3Jan2013 | | Comments Off on (COV) Covidien Drug Wins U.S. Food and Drug Administration Approval | Continued

(COV) Covidien Remains at Neutral

We have reiterated our Neutral recommendation on leading health care products maker, Covidien plc. (COV), with a target price of $60.

The company’s adjusted earnings per share (from continuing operations) of $1.02 for the...

1Jan2013 | | Comments Off on (COV) Covidien Remains at Neutral | Continued

(COV) Covidien plc Presents Positive Study Results

Covidien plc. (COV), a large-cap healthcare products company, has announced the five-year results of the ClosureFAST Long-Term European Multi-Center Study. The study revealed that the

28Dec2012 | | Comments Off on (COV) Covidien plc Presents Positive Study Results | Continued

(BSX) Boston Scientific Corporation Initiates Ingevity Trial

Boston Scientific Corporation (BSX) recently commenced a trial for its next-generation Ingevity pacing leads. The first patient was implanted to evaluate the safety, effectiveness and

27Dec2012 | | Comments Off on (BSX) Boston Scientific Corporation Initiates Ingevity Trial | Continued

(THOR) Thoratec Soars to 52-Week High

Shares of Thoratec Corp (THOR) reached a 52-week high of $39.50 on Tuesday, December 11, 2012. The medical device stock continues to edge past resistance levels and soared to another 52-week high. The closing price as of December...

17Dec2012 | | Comments Off on (THOR) Thoratec Soars to 52-Week High | Continued

(THOR) Thoratec Corporation – Bull of the Day

We maintain our recommendation for Thoratec Corp. (THOR) at Outperform. Its earnings per share of $0.44 in the third quarter beat the Zacks Consensus Estimate. The company achieved 27% unit growth for HeartMate II in the third quarter.

Thoratec’s...

16Dec2012 | | Comments Off on (THOR) Thoratec Corporation – Bull of the Day | Continued

(BAX) Baxter Presents Study Outcome

Baxter International (BAX) recently revealed critical Phase I/III study outcomes analyzing the efficacy and safety of BAX 326. This is an investigational recombinant factor IX protein, which is utilized for prophylaxis and therapy...

11Dec2012 | | Comments Off on (BAX) Baxter Presents Study Outcome | Continued

(THOR) Thoratec Corporation – Bull of the Day

We maintain our recommendation for Thoratec Corp. (THOR) at Outperform. Its earnings per share of $0.44 in the third quarter beat the Zacks Consensus Estimate. The company achieved 27% unit growth for HeartMate II in the third quarter.

Thoratec’s...

10Dec2012 | | Comments Off on (THOR) Thoratec Corporation – Bull of the Day | Continued

(THOR) Thoratec Authorizes New Share Repurchase

Thoratec Corp. (THOR), a leader in mechanical circulatory assistance devices, recently revealed that its board of directors has approved the repurchase of as much as $150 million of its common stock. The earlier authorization lapsed...

3Dec2012 | | Comments Off on (THOR) Thoratec Authorizes New Share Repurchase | Continued

(VVUS) Vivus Misses Third Quarter Estimates

Vivus Inc. (VVUS) reported a loss of 40 cents per share in the third quarter of 2012, wider than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago loss of 10 cents per share. Higher selling, general and administrative...

9Nov2012 | | Comments Off on (VVUS) Vivus Misses Third Quarter Estimates | Continued

(THOR) Thoratec Upgraded to Outperform

We upgrade our recommendation for Thoratec Corp. (THOR) to Outperform. HeartMate II unit sales rose 22% in the six months ending June 30, 2012 wrapping up a robust half year.

Heart failure is a terminal degenerative condition...

23Oct2012 | | Comments Off on (THOR) Thoratec Upgraded to Outperform | Continued

(OSUR) OraSure Technologies Unveils In-Home HIV test

OraSure Technologies (OSUR), a provider of medical devices and technologies to diagnose critical medical conditions, recently announced the availability of its OraQuick in-home HIV test at retail outlets and online, across the U.S.

The...

23Oct2012 | | Comments Off on (OSUR) OraSure Technologies Unveils In-Home HIV test | Continued

(THOR) Thoratec Corporation – Bull of the Day

We upgrade our recommendation for Thoratec Corporation (THOR) to Outperform. HeartMate II units rose 22% in the six months ending June 30, 2012 wrapping up a robust half-year. Its competitor, HeartWare, has filed a PMA for a similar...

10Oct2012 | | Comments Off on (THOR) Thoratec Corporation – Bull of the Day | Continued

(IART) Integra LifeSciences Holdings Corporation Exhibits Neuro Product Line

Medical products company, Integra LifeSciences Holdings Corporation (IART) is demonstrating its MAYFIELD Composite Series Cranial Stabilization product line at the Congress of Neurological Surgeons (“CNS”) annual meet...

10Oct2012 | | Comments Off on (IART) Integra LifeSciences Holdings Corporation Exhibits Neuro Product Line | Continued

(MR) Mindray Medical International Limited to Display at CMEF

Chinese medical devices major Mindray Medical International Limited (MR) recently revealed that it will showcase over 90 offerings at the 68th China International Medical Equipment Fair (CMEF) to be held in Sichuan, China during the...

9Oct2012 | | Comments Off on (MR) Mindray Medical International Limited to Display at CMEF | Continued

(VVUS) Vivus Expects European Setback

Vivus Inc. (VVUS) recently announced that it expects the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to recommend against the approval of its weight-loss drug, Qsiva, next month. The...

9Oct2012 | | Comments Off on (VVUS) Vivus Expects European Setback | Continued

(COO) T-Mobile Appoints New CEO

T-Mobile USA – the fourth largest telecom carrier in the U.S. – recently appointed John Legere as Chief Executive Officer, effective this month.

John Legere will succeed the interim CEO Jim Alling, who will return back to his existing role of Chief Operating Officer (COO).

T-Mobile’s...

23Sep2012 | | Comments Off on (COO) T-Mobile Appoints New CEO | Continued

(COV) FDA Clears Covidien’s Exalgo Tablet

Mallinckrodt, the pharmaceuticals business of Covidien plc (COV), recently received the clearance of the U.S. Food and Drug Association (FDA) for the 32 mg strength of its Exalgo (hydromorphone HCI) Extended-Release Tablets (CII)....

28Aug2012 | | Comments Off on (COV) FDA Clears Covidien’s Exalgo Tablet | Continued

(COO) Management Changes at Body Central Corporation

Body Central Corp. (BODY) recently promoted Tom Stoltz to the position of the chief operating officer (COO) as well as the interim chief executive officer (CEO). Stoltz had been serving as the company’s executive vice president,...

28Aug2012 | | Comments Off on (COO) Management Changes at Body Central Corporation | Continued

(CFN) CareFusion Announces Voluntary Product Recall

Recently, CareFusion (CFN), a medical technology company, announced the voluntary recall of its Alaris Pump Module, Model 8100. The recalled lot was manufactured between October 2011 and February 2012.

The product recall was...

26Aug2012 | | Comments Off on (CFN) CareFusion Announces Voluntary Product Recall | Continued